NEUWAY Pharma Appoints Healthcare Sector Veteran Dr Jacques Mallet to its Advisory Board
9.9.2022 14:34:00 EEST | Business Wire | Press release
NEUWAY Pharma GmbH, « NEUWAY », a preclinical-stage biotechnology company specializing in the delivery of innovative biotherapeutic drugs through its proprietary EnPC® drug-delivery technology, announced today the appointment of Dr Jacques Mallet as an additional independent member of the Advisory Board.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220909005184/en/
Dr. Jacques Mallet (Photo: Business Wire)
Jacques Mallet, MD, previously served as SVP of Head of Portfolio Analytics/Corporate Strategy and Member of the Executive Leadership Team of Sanofi and is currently board member of several listed and private companies in the biotech and medtech sector.
"I’m delighted to join the Advisory Board to support NEUWAY in the development and growth of the company", said Dr Mallet. "I have been impressed by the great capabilities of the EnPC® drug-delivery technology and its therapeutic applications, which offers many advantages for drug developers and patients."
Dr Mallet brings more than 30 years of pharmaceutical industry experience within R&D, Pipeline Development and Corporate Strategy to NEUWAY, along with unique insights gained as a life-science venture capitalist in both in Europe and the United States. In addition to being responsible for investments at Auriga Partners, a French private-equity firm specializing in life sciences, Dr Mallet has also held executive positions in global consulting firms including Monitor Deloitte and Accenture.
Welcoming Dr Mallet, NEUWAY's Advisory Board Chairman and General Partner at Wellington Partners, Dr Rainer Strohmenger, said, "We are proud to have attracted such a distinguished expert to join the board of NEUWAY. Dr Mallet’s experience in clinical research and portfolio management, makes him an excellent fit for NEUWAY."
Dr Oliver Ernst, Chief Executive Officer of NEUWAY, added, "I am delighted to welcome Dr Mallet to our Board. With his extensive experience Dr Mallet will greatly support our corporate and product development efforts towards partnerships and the first clinical applications of our unique EnPC® drug-delivery technology.”
About NEUWAY Pharma
NEUWAY Pharma is developing an entirely novel class of biotherapeutics built around its proprietary Engineered Protein Capsules (EnPC®), which can cross the blood-brain barrier and deliver transformative neuropharmaceuticals for the treatment of disorders of the central nervous system (CNS).
Learn more at www.neuway-pharma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005184/en/
Contact information
NEUWAY Pharma Contact:
Christine Kuhn
+49 228-522198-0
kuhn@neuway-pharma.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The Estée Lauder Companies Unveils Mastering Skin Longevity, a Breakthrough Scientific Innovation Platform Advancing the Next Era of Skin Science6.11.2026 16:00:00 EET | Press release
At the China International Import Expo (CIIE), The Estée Lauder Companies Inc. (NYSE: EL) today unveiled Mastering Skin Longevity, a breakthrough scientific innovation platform designed to advance the next era of skin science and transformative product innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261106776704/en/ The Estée Lauder Companies' Skin Longevity Clock serves as the visual representation for the Mastering Skin Longevity scientific innovation platform. Moving beyond the study of individual Hallmarks of Aging, the platform focuses further upstream on the Master Regulators of Skin Longevity. These interconnected biological pathways and proteins influence multiple hallmarks at once. By deepening understanding of these systems and how they help support skin’s ability to repair, adapt and regenerate, Mastering Skin Longevity will guide the Company’s discovery across ingredients, technologies, formulations an
IntouchCX Recognized for Operations led AI and End to End CX Transformation by HFS Research6.11.2026 16:00:00 EET | Press release
IntouchCX a global leader in AI-powered customer experience (CX) management, trust and safety, digital engagement, and back-office operations, has been positioned in the Horizon 2 end-to-end experience transformation, in the HFS Horizons Customer Experience Services 2026 report for its operations led approach to AI adoption and its model connecting advisory with delivery, from strategy through frontline executions. HFS Research evaluates customer experience service providers based on their capabilities, innovation, and potential to deliver value. The 2026 report examines how providers are helping businesses adopt AI, improve customer experiences and strengthen operations. “AI transformation delivers the greatest value when strategy, technology, and operations work together,” said Brent Stevenson, Chief Experience Officer at IntouchCX. “Our approach and expertise goes beyond technology. We identify business challenges and build the right solutions by connecting the dots between data, wo
Experian Named a Leader in 2026 IDC MarketScape for Worldwide Decision Intelligence Platforms6.11.2026 16:00:00 EET | Press release
Experian today announced it has been named a Leader in the IDC MarketScape: Worldwide Decision Intelligence Platforms 2026 Vendor Assessment (Doc #US54118426, September 2026), which evaluates providers helping organizations design, engineer and orchestrate increasingly complex decisions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261106302874/en/ IDC MarketScape positions Experian as a Leader in its 2026 vendor assessment of worldwide decision intelligence platform providers. “As organizations embed AI into more consequential decisions, the combination of trusted data, advanced analytics and strong governance becomes increasingly important,” said Keith Little, President of Experian Software Solutions. “Experian brings those capabilities together with decisioning, fraud and identity to help organizations make better decisions with greater speed and confidence.” The Experian Ascend Platform provides a unified analytics and
Midas Atlantic Partners, in Partnership With the Najafi Companies, Has Entered Into a Put Option Agreement With Sylvamo Relating to the Potential Acquisition of Its European Operations6.11.2026 13:04:00 EET | Press release
Midas Atlantic Partners (“Midas Atlantic”), in partnership with The Najafi Companies, has signed a put option agreement with Sylvamo Corporation (“Sylvamo”) relating to the potential acquisition of its European operations (the “Business”). The transaction comprises Sylvamo’s uncoated freesheet paper mills in Saillat and Nymölla, as well as its forestry and supporting business operations across Europe. Closing is expected in the first quarter of 2027, once the required consultation processes are completed and regulatory approvals are obtained. The Business is a leading European producer of uncoated woodfree (UWF) paper for office and commercial printing. Its product portfolio spans cut-size office paper, sold under its own brands such as REY and Multicopy as well as on behalf of major OEM and office supplies customers, and paper reels for commercial printers and converters. Headquartered in Belgium, with two large-scale, vertically integrated pulp and paper mills, it serves a longstandi
Suzano Reports 36% Increase in Third Quarter Net Revenue Following Consolidation of Arbex6.11.2026 01:23:00 EET | Press release
Suzano (B3: SUZB3 / NYSE: SUZ) , the world’s largest pulp producer, announces its results for the third quarter of 2026 (3Q26), which for the first time include Arbex, the joint venture between Suzano and Kimberly-Clark established in July this year. Driven primarily by the consolidation of Arbex’s contribution, Suzano reported net revenue of BRL16.5 billion, an increase of 36% on the same period last year and a new quarterly record in the company’s 102-year history. Adjusted EBITDA totaled R$5.7 billion in 3Q26, up 9% on the same basis of comparison. Operating cash generation reached R$3.8 billion, an increase of 12%. Net income totaled R$2.1 billion. As announced following the completion of the transaction with Kimberly-Clark, Suzano holds a 51% equity interest in Arbex and will therefore fully consolidate the joint venture’s financial statements from this quarter onwards.1 “This quarter marks the beginning of a new phase for Suzano. With Arbex, we are now a broader business, both ge
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom